FogPharma raises $178m in Series D funding round
FogPharma, a Cambridge, Masachussetts-based biopharmaceutical company developing helicon polypeptides, has raised $178 million in a Series D funding round. The round includes new investors ARCH Venture Partners, Milky Way Investments, Fidelity Management & Research Company, and existing investors VenBio Partners, Deerfield Management, GV, Cormorant Asset Management, T Rowe Price Associates,
